Researchers at the University of California, San Francisco, set out to examine how cannabis affects heart rhythm in real time. They equipped habitual users with continuous monitors and randomly assigned inhalation or abstinence each day over two weeks. The approach allowed direct comparison of heart activity under controlled conditions within the same individuals.
The study, known as the MARY-JANE trial, focused on cardiac ectopy, or premature beats that can signal arrhythmia risk. Participants also wore devices to track activity, sleep, and glucose levels. This design helped isolate the acute effects of cannabis from other lifestyle factors.
Unexpected Reduction in Premature Beats
Habitual cannabis users recorded roughly 9 percent fewer premature heartbeats on days they inhaled the substance compared with days they abstained. The drop was driven mainly by a 10 percent decline in premature atrial contractions. Premature ventricular contractions showed no meaningful change.
Each instance of inhalation correlated with a small additional reduction in ectopic beats. No significant shifts appeared in step counts, sleep duration, or glucose readings. The findings emerged from a pragmatic crossover design that randomized daily instructions via text or app.
Why the Result Surprised the Team
Investigators had expected cannabis to increase irregular beats based on prior observational data. Instead, the randomized evidence pointed in the opposite direction. Senior author Gregory Marcus noted that the outcome contradicted the original hypothesis and underscored the value of controlled trials when expectations are challenged.
The trial enrolled 100 participants at the UCSF site. Each person followed the protocol for 14 days while wearing an external electrocardiographic monitor alongside other sensors. Adherence was verified through self-reports and device data.
Implications for Future Research
Marcus indicated that the results could point toward novel therapies for certain heart rhythm issues. Further work is needed to determine whether the observed reduction holds for different cannabis formulations, doses, or populations. Long-term cardiovascular outcomes also remain to be clarified.
The study adds nuance to ongoing discussions about cannabis and cardiac health. It highlights how continuous monitoring can uncover patterns that single snapshots or self-reported data might miss. Additional trials will help place these short-term findings in broader context.
Key Takeaways From the Monitoring Period
- Randomized daily cannabis inhalation linked to 9% fewer premature heartbeats overall.
- Effect concentrated on premature atrial contractions rather than ventricular ones.
- No detectable changes in activity, sleep, or glucose levels during the same window.
- Results based on within-person comparisons over 14 days of continuous tracking.
These observations invite closer examination of cannabis’s acute influence on the heart’s electrical activity. They also illustrate how wearable technology can refine understanding of everyday exposures. Continued investigation will determine whether the pattern translates into meaningful clinical applications.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.